"Express Mail" mailing label No.	EL 863 934 981 US	S
of Deposit	March 11, 2003	
I hereby certify that this paper or service under 37 CFR 1.10 on the 20231.	e date indicated above and is a	e United States Postal Service "Express Mail Post Office to Addressee" ddressed to the Assistant Commissioner for Patents, Washington, D.C.
(Typed or printed name of person		
(Signature of person mailing pape	er or fee)	Pate
		Attorney's Docket No. <u>004973-0</u>
		EG .
IN THE UN	NITED STATES PA	TENT AND TRADEMARK OFFICE  ) ) ) Group Art Unit: 1647 ) Examiner: Saoud, Christine J.
In re Patent Applicatio	on of	) <u> </u>
		)
Fiddes et al.		) Group Art Unit: 1647

## PRELIMINARY AMENDMENT

)

## <u>AND</u>

REPLY TO THE NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO **ACID SEQUENCE DISCLOSURES** 

**Assistant Commissioner for Patents** Washington, D.C. 20231

For: RECOMBINANT FIBROBLAST GROWTH

**FACTORS** 

Sir:

This Preliminary Amendment is submitted before the first Office Action for the above-referenced application in response to the Office Communications mailed on September 12 and October 24, 2002, regarding sequence requirements. The Examiner is requested to enter this amendment prior to examination of this application.

In the event that a telephone call could expedite the prosecution of this application, the Examiner is requested to telephone the undersigned at 650-622-2300 (extension 2340).

Applicat'	<b>"</b> No.:_	09/902,460
-----------	----------------	------------

## 1 PNOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be nobtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: Specification fails to comply with the sequence rules as the sequence are not identified by a SEQ ID NO. See MPEP 2422 and 37 CFR 1.821(d).
Аp	plicant Must Provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
_	
	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212
Pat	tentin Software Program Support
	Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY